文献速递眼底病与葡萄膜炎

全身白介素-6抑制与糖尿病视网膜病变发生及进展风险

Systemic Interleukin-6 Inhibition and Risk of Diabetic Retinopathy Development and Progression.
PubMed 文献 · Ophthalmology · 2026-08-03

这项回顾性倾向评分匹配队列研究基于美国TriNetX网络,评估全身IL-6抑制剂使用与成人糖尿病患者发生DR、DR进展、视力威胁并发症及视网膜干预风险的关联。主要分析纳入2605对匹配患者,结果显示IL-6抑制剂使用与5年NPDR、PDR、DME、VH风险显著降低相关,NVG无显著差异,抗VEGF、PRP和PPV使用也显著减少。

要点

  • IL-6抑制剂使用与5年NPDR风险降低相关(RR 0.50;95%CI 0.42-0.60)。
  • IL-6抑制剂使用与5年PDR、DME、VH风险降低相关,NVG无显著差异。
  • 基线NPDR患者中,IL-6抑制剂与进展至PDR、DME、VH、NVG及视网膜干预风险降低相关。

核心结论

  • 全身IL-6抑制剂使用与5年内DR发生、DR进展、视力威胁并发症及视网膜干预风险降低相关。
  • 需要前瞻性研究评估IL-6通路调节在糖尿病眼病中是否具有治疗作用。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,使用美国TriNetX网络2004年1月1日至2026年5月30日数据。
  • 主要分析纳入2605例IL-6抑制剂使用者和2605例匹配对照,均为1型或2型糖尿病成人。
  • 次要分析纳入每组1057例已知非增殖期DR(NPDR)的匹配患者。
  • 队列按基线特征、药物暴露、炎症疾病负担和眼科病史进行匹配。

主要发现

  • 主要分析中,IL-6抑制剂使用与5年NPDR风险显著降低相关(RR 0.50;95%CI 0.42-0.60)。
  • IL-6抑制剂使用与5年PDR风险显著降低相关(RR 0.47;95%CI 0.35-0.61)。
  • IL-6抑制剂使用与5年DME风险显著降低相关(RR 0.37;95%CI 0.27-0.51)。
  • IL-6抑制剂使用与5年VH风险显著降低相关(RR 0.41;95%CI 0.28-0.61),NVG无显著差异。
  • 5年时抗VEGF治疗、PRP和PPV使用也显著降低;基线NPDR患者中进展至PDR、DME、VH、NVG及视网膜干预风险降低。

关键数值与推荐

  • 主要结局为1、3、5年时发生NPDR、PDR、VH、DME、NVG及接受抗VEGF注射、PRP、PPV的风险比。
  • 敏感性分析比较IL-6抑制剂与玻璃体腔注射类固醇在重度NPDR或PDR患者中的结局,并评估IL-6抑制剂发生频率下的结局。

临床怎么用

  • 对于合并全身炎症性疾病且需要IL-6抑制剂治疗的糖尿病患者,眼科医生可关注其DR发生和进展风险可能较低。
  • IL-6抑制剂使用与视网膜干预需求减少相关,但需结合全身疾病和眼科情况综合评估。

局限性

  • 为回顾性队列研究,可能存在残余混杂。
  • 需要前瞻性研究验证IL-6通路调节对糖尿病眼病的治疗作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate whether systemic interleukin-6 (IL-6) inhibitor use is associated with reduced risk of incident diabetic retinopathy (DR), DR progression, vision-threatening complications, and retinal interventions in adults with diabetes. DESIGN: Retrospective propensity score-matched cohort study. PARTICIPANTS: Adults with type 1 or type 2 diabetes were identified using the US TriNetX network from January 1, 2004, through May 30, 2026. After 1:1 propensity score matching, the primary analysis included 2605 IL-6 inhibitor users and 2605 matched controls. The secondary analysis included 1057 matched patients per group with known nonproliferative DR (NPDR). METHODS: Cohorts were matched on baseline characteristics, medication exposure, inflammatory disease burden, and ophthalmic history. The primary analysis assessed incident DR among patients without baseline retinopathy. Secondary analyses evaluated progression from NPDR to proliferative DR (PDR) and compared IL-6 inhibitors with alternative immunosuppressants. Sensitivity analyses compared IL-6 inhibitors with intravitreal steroid injections among patients with severe NPDR or PDR and evaluated outcomes at IL-6 inhibitor occurrence frequency. MAIN OUTCOME MEASURES: Risk ratios for incident NPDR, PDR, vitreous hemorrhage (VH), diabetic macular edema (DME), neovascular glaucoma (NVG), and receipt of anti-VEGF injections, panretinal photocoagulation (PRP), and pars plana vitrectomy (PPV) at 1, 3, and 5 years. RESULTS: In the primary analysis, IL-6 inhibitor use was associated with significantly lower 5-year risks of NPDR [risk ratio (RR): 0.50; 95% confidence interval (CI): 0.42-0.60], PDR (RR: 0.47; 95% CI: 0.35-0.61), DME (RR: 0.37; 95% CI: 0.27-0.51), and VH (RR: 0.41; 95% CI: 0.28-0.61), with no significant difference in NVG. Use of anti-VEGF therapy, PRP, and PPV was also significantly lower at 5 years. Among patients with baseline NPDR, IL-6 inhibitor use was associated with lower 5-year risks of progression to PDR, DME, VH, NVG, and retinal interventions. Findings were consistent in active comparator analyses. CONCLUSIONS: Systemic IL-6 inhibitor use was associated with a lower risk of incident DR, DR progression, vision-threatening complications, and retinal interventions over 5 years. Prospective studies are needed to evaluate whether IL-6 pathway modulation may have a therapeutic role in diabetic eye disease. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Abdi A, Alshaikhsalama A, Zaidi Z, et al. Systemic Interleukin-6 Inhibition and Risk of Diabetic Retinopathy Development and Progression. Ophthalmology. 2026. PMID: 42546975. doi:10.1016/j.ophtha.2026.07.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。